Vol 43, Issue 2

Don't miss out on these CME articles! Test your knowledge here.

Psilocybin for depression nears approval; clinicians must manage medication interactions, avoiding lithium and MAOIs while monitoring vital signs and blunted effects.

How does MDMA-assisted therapy rewire fear circuits in PTSD and boost trust? Why has the FDA asked for more safety data? Learn more in this Special Report.

Psychedelic therapies surge in trials, but safety varies by substance—learn key benefits, risks, and why psychiatric history raises complications.

How are MDMA and psilocybin reshaping PTSD and depression care? Learn more in our Psychedelics Special Report.

Explore how TMS offers a World Anti-Doping Agency-safe, nondrug option for athletes.

Adjunctive lithium sharply reduces relapse and suicidal ideation, and attempts in patients with bipolar disorder and major depressive disorder.

Explore how seizure control, antiepileptics, and surgery can trigger psychosis in epilepsy, and what guides diagnosis and treatment.

Explore how glutamate and GABA balance brain excitation and inhibition, shaping development, learning, and disorders like depression, schizophrenia, and autism.

Explore the new Psychiatric Times digital issue, featuring articles, multimedia, and interactive learning to sharpen your clinical skills.

New evidence reframes antidepressant withdrawal: how common, how severe, and how to taper safely without mistaking symptoms for relapse.

Antidepressant withdrawal often mimics relapse; learn why hyperbolic tapering, informed consent, and slow cut-and-hold deprescribing reduce harm.